Precision medicine and sophisticated technologies have caused a paradigm shift in drug development, leading to programs with narrower indications, shorter development times and decreased costs. This shift in development has enabled programs to identify patients likely to respond to treatment, determine best dose, provide proof of biological mechanism, and present data in the exploratory setting for further downstream testing. Biomarkers are now an essential part of the immuno-oncology drug discovery and development processes, with more R&D investment allocated towards these targeted immune therapies. A biomarker-driven approach to developing targeted therapies enables risk mitigation throughout the drug development and commercialization process.
As immuno-oncology drug development involves utilizing biomarkers more for targeted therapies, you need a laboratory services partner who can work with you to develop a successful biomarker-driven approach. Having a comprehensive biomarker strategy for cancer therapeutics will impact your program by enabling risk mitigation throughout the drug development and commercialization process, and helping patient outcomes more cost-effectively.
Download this biomarker roadmap factsheet to determine the steps to a successful biomarker strategy that will drive your precision medicines across the drug development continuum.